Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells.

Authors: Cheng, Jiwen  Ye, Huama  Liu, Zhiyong  Xu, Chuanliang  Zhang, Zhensheng  Liu, Yan  Sun, Yinghao 
Citation: Cheng J, etal., J Cell Biochem. 2013 Jul;114(7):1510-8. doi: 10.1002/jcb.24492.
Pubmed: (View Article at PubMed) PMID:23297038
DOI: Full-text: DOI:10.1002/jcb.24492

Mesenchymal stem cells (MSCs) favor cancer growth by facilitating immunosuppression status in tumor microenvironment. However, the function and mechanism of MSCs in initiating and developing prostate cancer remains to be fully understood. In this study, we first found that MSCs promoted prostate cancer (PCa) tumor growth in vivo and cell proliferation in vitro by using PCs cell strain RM-1. Both exogenous and endogenous MSCs could be recruited into the tumor microenvironment by using bone-marrow transplantation model. We further demonstrated that PDGF-BB produced by RM-1 cell promoted MSCs proliferation in vivo and in vitro, which was abrogated by Si-RNA specific to PDGF-BB. And inflammatory cytokines, such as interferon gamma, tumor necrosis factor alpha, and anti-inflammatory cytokine transformation growth factor alpha, further increased the ability of RM-1 to produce PDGF-BB. Overall, PCa cells produced PDGF-BB favors the proliferation of MSCs, which may elicit immunosuppressive function and enable PCa cells to escape from the immunity surveillance in tumor inflammatory microenvironment.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13506769
Created: 2018-02-12
Species: All species
Last Modified: 2018-02-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.